CHIKUNGUNYA VIRUS

Clinical trials for CHIKUNGUNYA VIRUS explained in plain language.

Never miss a new study

Get alerted when new CHIKUNGUNYA VIRUS trials appear

Sign up with your email to follow new studies for CHIKUNGUNYA VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Completed 1

New chikungunya vaccine enters first human safety trial

⭐️ VACCINE ⭐️ Not yet recruiting

This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…

Matched conditions: CHIKUNGUNYA VIRUS

Phase: EARLY_PHASE1 • Sponsor: Gylden Pharma Ltd • Aim: ⭐️ VACCINE ⭐️

Last updated Jun 27, 2026 12:24 UTC

CHIKUNGUNYA VIRUS

Get alerted when new CHIKUNGUNYA VIRUS trials appear

New chikungunya vaccine enters first human safety trial